FAPI-guided radiation with cadonilimab and chemo for colorectal cancer spread to the abdomen
Treatments studied
Part of Cancer clinical trials.
This trial tests a new combination treatment for colorectal cancer that has spread only to the lining of the abdomen (peritoneum). It combines targeted radiation, an immunotherapy drug called cadonilimab, and standard chemotherapy to see if it can help control the disease better than current options.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have colorectal cancer that has spread only to the abdomen (peritoneum), not to other organs.
- Your tumor is a type called pMMR or MSS/MSI-L (this means your cancer cells have certain genetic markers).
- You have had your first round of chemotherapy (like FOLFOX or XELOX) and the cancer has grown or come back, but you have not yet had a second line of treatment.
- You have no significant fluid buildup in the abdomen (ascites) and no bowel blockage.
- You have not been treated with immunotherapy drugs (like PD-1 or PD-L1 inhibitors) before.
- You are able to eat normally and have no symptoms of bowel obstruction.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of oral chemotherapy, targeted therapy, and immunotherapy, with or without radiation, for people with advanced colorectal cancer that hasn't responded to at least two prior treatments. The goal is to see if this approach can help shrink tumors or slow the disease.
This trial tests a new combination of three medicines for people with a certain type of advanced colorectal cancer that has not been treated before. It aims to see if adding an immunotherapy drug (Cadonilimab) to standard chemotherapy and a targeted therapy (Bevacizumab) can help shrink tumors and delay disease progression.
This trial tests a combination of two drugs (cadonilimab and an anti-angiogenic agent) for advanced colorectal cancer that has a specific genetic feature (dMMR or MSI-H). It aims to find a new treatment option that might work better than current therapies.
This trial tests a combination of three drugs (given through a vein and a pill) plus a chemotherapy infusion directly into your belly for stomach cancer that has spread to the lining of the abdomen. It specifically looks at a marker called Claudin 18.2 to see if this treatment works better for people with that marker.
This trial combines a special type of radiation, immunotherapy, a targeted blood-vessel drug, and a chemotherapy pill for patients whose colorectal cancer has continued to grow after two prior treatments. The hope is that this combination can shrink tumors or slow down the cancer better than current options.
This trial tests a combination of a new immunotherapy (cadonilimab) with standard chemotherapy (capecitabine, oxaliplatin) and bevacizumab for people with metastatic colorectal cancer that has a RAS mutation or is located on the right side of the colon. The goal is to see if this combination works better than the current standard of care as a first treatment.
Hear when a new Peritoneal (Metastatic) Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.